Goldman Sachs Group Inc. Purchases 913,458 Shares of Glaukos Corporation $GKOS

Goldman Sachs Group Inc. boosted its holdings in Glaukos Corporation (NYSE:GKOS) by 209.0% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 1,350,425 shares of the medical instruments supplier’s stock after buying an additional 913,458 shares during the period. Goldman Sachs Group Inc.’s holdings in Glaukos were worth $152,476,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of GKOS. Natixis Advisors LLC boosted its stake in shares of Glaukos by 20.9% in the fourth quarter. Natixis Advisors LLC now owns 22,748 shares of the medical instruments supplier’s stock worth $2,568,000 after acquiring an additional 3,927 shares during the period. Norges Bank bought a new stake in Glaukos during the 4th quarter valued at approximately $60,536,000. Eurizon Capital SGR S.p.A. purchased a new position in Glaukos in the 4th quarter worth approximately $125,000. Zhang Financial LLC lifted its holdings in Glaukos by 5.7% in the 4th quarter. Zhang Financial LLC now owns 22,963 shares of the medical instruments supplier’s stock worth $2,593,000 after purchasing an additional 1,246 shares in the last quarter. Finally, Harbour Investments Inc. bought a new position in Glaukos in the 4th quarter worth approximately $86,000. 99.04% of the stock is owned by institutional investors.

Glaukos Stock Performance

NYSE:GKOS opened at $124.79 on Monday. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.43 and a quick ratio of 4.73. Glaukos Corporation has a 1 year low of $73.16 and a 1 year high of $148.11. The stock’s 50 day simple moving average is $122.29 and its two-hundred day simple moving average is $115.31. The company has a market cap of $7.33 billion, a price-to-earnings ratio of -38.05 and a beta of 0.83.

Glaukos (NYSE:GKOS) last posted its earnings results on Wednesday, April 29th. The medical instruments supplier reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.12. Glaukos had a negative return on equity of 6.92% and a negative net margin of 34.34%.The firm had revenue of $150.57 million during the quarter, compared to the consensus estimate of $137.00 million. During the same period in the prior year, the company earned ($0.22) EPS. The company’s quarterly revenue was up 41.2% compared to the same quarter last year. As a group, equities analysts anticipate that Glaukos Corporation will post -0.57 earnings per share for the current fiscal year.

Insider Buying and Selling at Glaukos

In other Glaukos news, COO Joseph E. Gilliam sold 19,573 shares of Glaukos stock in a transaction on Friday, May 1st. The shares were sold at an average price of $143.54, for a total value of $2,809,508.42. Following the completion of the transaction, the chief operating officer directly owned 73,419 shares of the company’s stock, valued at $10,538,563.26. This trade represents a 21.05% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Alex R. Thurman sold 10,000 shares of the business’s stock in a transaction dated Thursday, April 30th. The stock was sold at an average price of $140.00, for a total transaction of $1,400,000.00. Following the completion of the sale, the chief financial officer owned 43,681 shares in the company, valued at approximately $6,115,340. This trade represents a 18.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 45,930 shares of company stock worth $6,321,363 over the last three months. 5.90% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Stifel Nicolaus set a $170.00 price objective on shares of Glaukos in a report on Thursday, April 30th. JPMorgan Chase & Co. upped their target price on shares of Glaukos from $120.00 to $140.00 and gave the stock an “overweight” rating in a research report on Thursday, April 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Glaukos in a research note on Tuesday, April 21st. Citigroup lifted their price target on shares of Glaukos from $135.00 to $140.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Finally, BTIG Research boosted their price target on shares of Glaukos from $141.00 to $162.00 and gave the stock a “buy” rating in a research note on Thursday, May 21st. Twelve research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $146.17.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.